Innova Therapeutics

Innova Therapeutics is a private, preclinical-stage biotech developing a first-in-class monoclonal antibody platform targeting the SFRP2 protein, a novel oncology target linked to poor patient outcomes. The company's lead candidate, IVT-8086, is a humanized mAb being explored as a monotherapy and in combination for difficult-to-treat solid tumors. Led by an experienced team with a successful exit history, Innova is also developing a companion diagnostic for SFRP2 to aid in early detection and prognosis. The company is positioned to address significant unmet needs in oncology, though it faces the inherent risks of novel target validation and early-stage development.

Monoclonal antibody platform targeting the SFRP2 protein, a target highly expressed in solid tumors and correlated with poor patient outcomes. Includes a companion diagnostic program for SFRP2 detection and monitoring.

Innova operates in the highly competitive solid tumor oncology space. While first-in-class for SFRP2, it will compete against numerous approved and investigational therapies, including other antibody-drug conjugates, immunotherapies, and targeted agents. Its success depends on demonstrating superior or complementary efficacy in defined patient populations.